{"disease":{"id":"nonsmall-cell-lung-cancer","name":"nonsmall cell lung cancer"},"drugs":{"marketed":[{"drug_id":"ipilimumab","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Yervoy","generic_name":"ipilimumab","company_name":"Bristol-Myers Squibb","drug_phase":"discontinued","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"CTLA-4-directed Blocking Antibody","quality_score":0,"revenue":"2900","mechanism":"Yervoy blocks a protein called CTLA-4, which normally helps to turn off the immune system, allowing it to attack cancer cells."},{"drug_id":"cemiplimab","indication_name":"Nonsmall cell lung cancer without mutation in epidermal growth factor receptor","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Libtayo","generic_name":"CEMIPLIMAB","company_name":"Regeneron Pharmaceuticals ","drug_phase":"marketed","molecular_target":"PD-1","drug_class":"","quality_score":64,"revenue":"1452","mechanism":"Cemiplimab-rwlc binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, enhancing the immune response against tumors."},{"drug_id":"yervoy","indication_name":"Metastatic nonsmall cell lung cancer with no sensitising EGFR mutation or ALK translocation","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Yervoy","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"Cytotoxic T-lymphocyte protein 4","drug_class":"","quality_score":16,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06996249","title":"Prospective Data Collection Initiative on Thoracic Malignancies","phase":"","overall_status":"RECRUITING","enrollment_count":12000,"lead_sponsor_name":"Dutch Society of Physicians for Pulmonology and Tuberculosis","has_results":false},{"nct_id":"NCT06607393","title":"CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3]","phase":"","overall_status":"COMPLETED","enrollment_count":851,"lead_sponsor_name":"Aetion, Inc.","has_results":false},{"nct_id":"NCT03088540","title":"Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":712,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT06293833","title":"Implementation of Lung Cancer Screening in the First Line Zone of ZORA (Flanders), Using a Low Dose CT-scan","phase":"NA","overall_status":"UNKNOWN","enrollment_count":700,"lead_sponsor_name":"University Hospital, Antwerp","has_results":false},{"nct_id":"NCT03940846","title":"CT-based Radiomic Signature Can Identify Adenocarcinoma Lung Tumor Histology","phase":"","overall_status":"UNKNOWN","enrollment_count":650,"lead_sponsor_name":"Maastricht University","has_results":false},{"nct_id":"NCT02981108","title":"A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":364,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":true},{"nct_id":"NCT03059641","title":"Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China","phase":"","overall_status":"COMPLETED","enrollment_count":300,"lead_sponsor_name":"Geneplus-Beijing Co. Ltd.","has_results":false},{"nct_id":"NCT04654520","title":"A Randomized Study of Primary Tumor Radiotherapy for Patients With Stage Ⅳ NSCLC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":290,"lead_sponsor_name":"Guizhou Medical University","has_results":false},{"nct_id":"NCT05014815","title":"Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":272,"lead_sponsor_name":"BeiGene","has_results":true},{"nct_id":"NCT04566432","title":"Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy in ICIs Treated NSCLC Patients","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"Geneplus-Beijing Co. Ltd.","has_results":false},{"nct_id":"NCT05275374","title":"XP-102 and XP-102 in Combination With Trametinib in Advanced Solid Tumor Patients With a BRAF V600 Mutation","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":221,"lead_sponsor_name":"Xynomic Pharmaceuticals, Inc.","has_results":false},{"nct_id":"NCT02562027","title":"SBRT (Stereotactic Body Radiation Therapy) vs. Surgery in High Risk Patients With Early Stage Lung Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":217,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT03838588","title":"The Tracking Molecular Evolution for NSCLC (T-MENC) Study","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Geneplus-Beijing Co. Ltd.","has_results":false},{"nct_id":"NCT06813365","title":"Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":190,"lead_sponsor_name":"Dizal Pharmaceuticals","has_results":false},{"nct_id":"NCT03258671","title":"IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":160,"lead_sponsor_name":"LuBing","has_results":false},{"nct_id":"NCT03512847","title":"Predictive Gene Profiles and Dynamic Measurement of Treatment Response in Metastatic Non-small Cell Lung Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Zealand University Hospital","has_results":false},{"nct_id":"NCT02952729","title":"Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":120,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT03512015","title":"A Mobile Supportive Care App for Patients With Metastatic Lung Cancer","phase":"NA","overall_status":"UNKNOWN","enrollment_count":120,"lead_sponsor_name":"Bocconi University","has_results":false},{"nct_id":"NCT03044626","title":"Fostering Efficacy of Anti - PD-1 - Treatment: Nivolumab Plus Radiotherapy in Advanced NSCLC","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":101,"lead_sponsor_name":"AIO-Studien-gGmbH","has_results":false},{"nct_id":"NCT03444766","title":"Study of Nivolumab for Advanced Cancers in India","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT03769805","title":"Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC","phase":"NA","overall_status":"UNKNOWN","enrollment_count":83,"lead_sponsor_name":"The First Affiliated Hospital with Nanjing Medical University","has_results":false},{"nct_id":"NCT03499678","title":"Lung Cancer Screening Using DNA Methylation Changes in Circulated Tumor and PBMC DNA","phase":"","overall_status":"TERMINATED","enrollment_count":81,"lead_sponsor_name":"HKGepitherapeutics","has_results":false},{"nct_id":"NCT05358249","title":"Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":74,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04900935","title":"Patient-centered, Optimal Integration of Survivorship and Palliative Care","phase":"NA","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Massachusetts General Hospital","has_results":false},{"nct_id":"NCT03987087","title":"A Randomized Study of Primary Tumor Radiotherapy for Patients With MPE Stage IV NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":68,"lead_sponsor_name":"Guizhou Medical University","has_results":false},{"nct_id":"NCT06147570","title":"A Study of HS-10365 in Patients With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":62,"lead_sponsor_name":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","has_results":false},{"nct_id":"NCT03415126","title":"A Study of ASN007 in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Asana BioSciences","has_results":false},{"nct_id":"NCT05082610","title":"A Study of HMBD-002, a Monoclonal Antibody Targeting VISTA, as Monotherapy and Combined With Pembrolizumab, in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":48,"lead_sponsor_name":"Hummingbird Bioscience","has_results":false},{"nct_id":"NCT02905591","title":"A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":43,"lead_sponsor_name":"Joseph J. Cullen, MD, FACS","has_results":false},{"nct_id":"NCT03256721","title":"Compare Apatinib Plus Chemotherapy Drug Versus Chemotherapy Drug as Second-line Treatment in NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":37,"lead_sponsor_name":"Fuzhou General Hospital","has_results":false},{"nct_id":"NCT05860296","title":"Testing Experimental Anti-cancer Drug SLC-391 With an Approved Immunotherapy Drug, Pembrolizumab, for Advanced Lung Cancers","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":36,"lead_sponsor_name":"SignalChem Lifesciences Corporation","has_results":false},{"nct_id":"NCT03612154","title":"Study of Lorlatinib in ROS1 Rearranged NSCLC","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":35,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT06209229","title":"Role of Neutrophils and Electro-bioluminescence in the Rehabilitation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"MIPO Clinic","has_results":false},{"nct_id":"NCT06667154","title":"Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":33,"lead_sponsor_name":"Aline Fusco Fares, MD","has_results":false},{"nct_id":"NCT04396340","title":"First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":31,"lead_sponsor_name":"Mersana Therapeutics","has_results":false},{"nct_id":"NCT03778814","title":"TCR-T Cell Immunotherapy of Lung Cancer and Other Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Second Affiliated Hospital of Guangzhou Medical University","has_results":false},{"nct_id":"NCT03322072","title":"Calypso Guided High Precision Stereotactic Ablative Radiosurgery for Lung TUmours Using Real-Time Tumour Tracking & Respiratory Gating","phase":"NA","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"CancerCare Manitoba","has_results":false},{"nct_id":"NCT03753685","title":"X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":27,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06060964","title":"Enabling Remote Access to Breathe Easier: A Novel Approach to Improve Symptom Management","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":24,"lead_sponsor_name":"University of South Carolina","has_results":false},{"nct_id":"NCT02299141","title":"Nintedanib in Molecularly Selected Patients With Advanced Non-Small Cell Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04314895","title":"Trial of NanoPac Intratumoral Injection in Lung Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"NanOlogy, LLC","has_results":true},{"nct_id":"NCT02193152","title":"Pazopanib in Molecularly Selected Patients With Advanced NSCLC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT04040244","title":"Exhaled Breath Analysis to Predict Risk of Symptomatic Pneumonitis","phase":"NA","overall_status":"TERMINATED","enrollment_count":16,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":true},{"nct_id":"NCT03450330","title":"Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":10,"lead_sponsor_name":"Dizal Pharmaceuticals","has_results":false},{"nct_id":"NCT02342353","title":"Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05860582","title":"A Study of [14C]GB491 in Male Healthy Subjects","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"Genor Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT02431169","title":"Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression","phase":"","overall_status":"TERMINATED","enrollment_count":5,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT02669914","title":"MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":4,"lead_sponsor_name":"Washington University School of Medicine","has_results":true},{"nct_id":"NCT05873439","title":"Genomically Guided Radiation Dose Personalization in Locally Advanced NSCLC","phase":"EARLY_PHASE1","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT03825510","title":"Immunotherapy SBRT Sensitization of the Programmed Death-1 (PD-1) Effect","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":3,"lead_sponsor_name":"Crozer-Keystone Health System","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}